What Wakamoto Pharmaceutical does

Wakamoto Pharmaceutical Co., Ltd. (TYO:4512) is a Japan-domiciled, publicly-listed pharmaceutical company tracing its origins to 1926 rice-bran and yeast research, with its flagship "Kyoryoku Wakamoto" digestive product launched in 1929. The company's core differentiator is proprietary koji mold cultivation technology — specifically the Aspergillus oryzae NK strain (discovered 1936 and designated Japan's national fungus in 2006) — combined with the proprietary WB2000 Enterococcus faecium lactic acid bacteria strain cultivated on rice/barley germ medium. These biological assets underpin three product pillars: (1) OTC digestive medicines and quasi-drugs (Kyoryoku Wakamoto, Granular Wakamoto, Wakamoto Seichoyo), (2) oral care (Avant Bise toothpaste/oral tablets, Coral Epsilon), and (3) medical-professional nutritional supplements (Optiade DE/ML MACULAR/GL developed with Tohoku University) and medical devices (Macueide eye injection).

The company generates revenue through four primary streams: OTC pharmaceuticals sold via Japanese pharmacies and drugstores, health functional foods including the Optiade series, oral care products, and direct e-commerce sales through its own shop and Rakuten marketplace. Pricing follows standardized unit pricing per package (e.g., Optiade GL at ¥3,240 for 120 tablets), with retail prices publicly disclosed and stable across channels. Go-to-market is sales-led through traditional OTC retail augmented by content marketing on health information websites and social media channels (YouTube, X, Instagram, LINE).

The business model is product-centric, not platform-centric, with revenue derived from one-time unit purchases rather than subscriptions or licensing. Manufacturing is concentrated at the GMP-compliant Sagamihara Factory in Kanagawa, with branch sales offices in Tokyo (headquarters), Osaka, Kanto, Sendai, and Hiroshima. Operations are domestic-only except for the May 2026 China launch of Macueide Eye Injection. The company has 251-500 employees and is governed under Japanese GAAP as a non-consolidated publicly-listed entity on the Tokyo Stock Exchange.

Name

Wakamoto Pharmaceutical

Legal name

わかもと製薬株式会社 (Wakamoto Pharmaceutical Co., Ltd.)

Website

https://wakamoto-pharm.co.jp

Company type

Private

Founded year

1926

Operating status

Operating

Headcount range

11–50 employees

Short description

Wakamoto Pharmaceutical is a Japan-domiciled, publicly-listed OTC pharmaceutical company founded in 1926, specializing in digestive health, oral care, and women's wellness products built on its proprietary Aspergillus oryzae NK koji mold and WB2000 lactic acid bacteria strains, sold through Japanese pharmacies and e-commerce channels.

Ownership category

akta.pro rank

Product category

OTC Pharmaceuticals and Health Supplements

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113), Soap and Cleaning Compound Manufacturing (32561)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Gastrointestinal & Digestive Health (HLAIADAD)

akta.pro secondary industries

Digestive Health OTC (Antacids, Laxatives, Anti-diarrheals, Probiotics OTC) (CRADAMAE), Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays) (CRADAMAG), Women’s Health (OTC Gynecologic) (HLAIADAJ)

Keywords

• OTC digestive medicines
• Health functional foods
• Oral care products
• Femtech supplements
• Pharmaceutical manufacturing

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices6 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. OTC Pharmaceuticals (一般用医薬品): Sales of OTC胃肠药 products including 強力わかもと, 顆粒わかもと, and わかもと整腸薬 through pharmacies and retail stores. 強力わかもと transitioned from pharmaceutical to quasi-drug (医薬部外品) status in 2004.
2. Health Functional Foods (健康食品): Sales of nutritional supplements including オプティエイド series (DE, ML MACULAR, GL) and フェムテック products targeting women's health.
3. Oral Care Products (オーラルケア製品): Sales of dental care products including アバンビーズ toothpaste series, アバンビーズ オーラルタブレット, and コーラルε.
4. E-commerce Direct Sales: Direct sales through company's own online shop (wakamoto-shopping.jp) and Rakuten marketplace.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Wakamoto Pharmaceutical manufactures and sells OTC digestive medicines, intestinal regulators, oral care products, women's femtech health products, and medical-grade nutritional supplements. Its core products combine proprietary cultures of Aspergillus oryzae NK strain, lactic acid bacteria (WB2000), and beer yeast. The company also produces ophthalmic medical devices such as vitreous visualization agents (Maqueid Intraocular Injection 40mg).

Product overview

Wakamoto Pharmaceutical is a Japanese pharmaceutical company offering a diversified portfolio of OTC healthcare products and medical nutritional supplements. The core product line centers on digestive medicines (強力わかもと, 顆粒わかもと, わかもと整腸薬) containing proprietary cultures of Aspergillus oryzae NK菌, lactic acid bacteria, and beer yeast. The oral care line includes アバンビーズ toothpaste and oral tablets, plus コーラルε toothpaste for periodontal care. The femtech line (フェミフローラ series) addresses women's intimate health. The medical professional line (オプティエイド series) provides ophthalmology-targeted nutritional supplements developed through academic partnerships. The company also manufactures medical devices including vitreous visualization agents.

Differentiator

Problem solved

Functional benefit

Brands

• 強力わかもと (Kyoryoku Wakamoto): Core digestive/intestinal health product (designated quasi-drug) containing Aspergillus oryzae NK strain culture, lactic acid bacteria culture, and dried beer yeast.
• 顆粒わかもと (Granular Wakamoto)
• わかもと整腸薬 (Wakamoto Seichoyo)
• アバンビーズ (Avant Bise)
• コーラルε (Coral Epsilon)
• アレジフェンス (Arezifensu)
• フェミフローラ (Femi Flora)
• オプティエイド (Optiade)
• アバンビーズ オーラルタブレット (Avant Bise Oral Tablet)

Products and services

• Kyoryoku Wakamoto (強力わかもと) Digestive medicine containing Aspergillus oryzae NK strain culture, lactic acid bacteria culture, and dried beer yeast; provides digestive, intestinal regulation, and nutritional supplementation functions. Designated quasi-drug in Japan.
• Granular Wakamoto (顆粒わかもと) Granular formulation of the core digestive medicine product with the same active ingredients (Aspergillus oryzae NK culture, lactic acid bacteria culture, dried beer yeast).
• Wakamoto Seichoyo (わかもと整腸薬) Intestinal regulator containing 2 strains of Bifidobacterium and Lactobacillus gasseri; supports gut flora balance and digestive health.
• Avant Bise Oral Tablet (アバンビーズ オーラルタブレット) Oral tablet containing WB21 lactic acid bacteria and tea catechins for bad breath prevention and oral care.
• Avant Bise (アバンビーズ) Toothpaste containing live WB2000 lactic acid bacteria for oral microbiome balance and bad breath prevention.
• Coral Epsilon (コーラルε) Dental toothpaste with 6 medicinal ingredients for periodontal disease prevention, gingivitis, cavity prevention, and tartar control; contains epsilon-aminocaproic acid.
• Arezifensu (アレジフェンス) Healthcare product for immune support and health maintenance.
• Femi Flora (フェミフローラ) Women's health supplement line for feminine hygiene and wellness.
• Femi Floraine Delicate Moisturizing Cream (フェミフローライン デリケート保湿クリーム) Delicate moisturizing cream for intimate area care.
• Femi Flora Folic Acid Plus (フェミフローラ 葉酸プラス) Folic acid supplement for women's health.
• Femi Flora Soy Isoflavone Maca & GABA (フェミフローラ 大豆イソフラボン マカ＆ギャバ) Women's health supplement containing soy isoflavone, maca, and GABA.
• Optiade DE (オプティエイドDE) Nutritional functional food (Vitamins C, E, Zinc) containing original WB2000 lactic acid bacteria, lactoferrin, EPA/DHA, and lutein; developed from ophthalmology research for tear production support; 60 tablets, suggested retail 3,240 yen.
• Optiade ML MACULAR (オプティエイドML マキュラ) Food with functional claims containing lutein (20mg), zeaxanthin, vitamins C/E, zinc, and copper; supports macular pigment density and contrast sensitivity; 90 tablets, suggested retail 3,456 yen; filing number D145.
• Optiade GL (オプティエイドGL) Nutritional functional food (Vitamin C) containing antioxidants: hesperidin, crocetin, Indian dates extract, and vitamin C; developed from joint research with Tohoku University Graduate School of Medicine Ophthalmology Department; 120 tablets, suggested retail 3,240 yen.
• Maqueid Intraocular Injection 40mg (マキュエイド眼注用40 mg) Ophthalmic surgical aid — vitreous visualization agent used during vitreoretinal surgery.

Quantifiable outcome

• Vitamin B1, 9 vitamins total, 9 essential amino acids (16 types), 7 minerals including iron, calcium, magnesium from beer yeast
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor and core.

• ボシュロム・ジャパン (Bausch & Lomb Japan)minorStrategic or Co-development Partner · 29 February 2012Medical supplement co-sales partnership announced in February 2012 for ophthalmic supplements targeting healthcare professionals.
• Dental Product Partner (for oral care promotions)minorGTM or Marketing Partner · 15 December 2010Co-promotion partnership in the oral care product domain announced in December 2010 for joint marketing activities.
• 東北大学院医学系研究科 眼科学分野 (Tohoku University Graduate School of Medicine, Department of Ophthalmology)coreStrategic or Co-development PartnerJoint research partnership with Tohoku University's Department of Ophthalmology leading to the development of the オプティエイド series supplements. The オプティエイドML MACULAR and オプティエイドGL products were developed based on this collaborative research.
• 日本製薬工業協会 (Japan Pharmaceutical Manufacturers Association)minorOthersMember of the Japan Pharmaceutical Manufacturers Association (JPMA), contributing to the pharmaceutical industry's voice and standards.
• 日本OTC医薬品協会 (Japan OTC Medicines Association)minorOthersMember of the Japan OTC (Over-The-Counter) Medicines Association, participating in self-medication promotion campaigns.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Taisho Pharmaceutical: Taisho Pharmaceutical is one of Japan's largest OTC specialists with strong positions in digestive remedies (Seirogan-adjacent categories), energy drinks, and consumer health. As a larger incumbent, Taisho competes with Wakamoto across most OTC categories and sets the benchmarks for Japanese OTC scale and drugstore penetration.
• Daiichi Sankyo Healthcare: Daiichi Sankyo Healthcare is the OTC and consumer health arm of Daiichi Sankyo, one of Japan's largest pharmaceutical groups. It overlaps with Wakamoto in OTC digestive and oral care categories but operates from a much larger corporate parent with significantly greater R&D and marketing resources.
• Tsumura & Co. Tsumura is a Japanese pharmaceutical company specializing in Kampo (traditional herbal) medicines for gastrointestinal and women's health — overlapping Wakamoto's digestive and Femiflora franchises. Listed on TSE with a broadly similar small/mid-cap profile and domestic-focused distribution.

Direct peers

• Rohto Pharmaceutical: Rohto Pharmaceutical is a Japanese OTC healthcare company operating in eye care, gastrointestinal, and oral care categories — directly overlapping Wakamoto's Optiade ophthalmology and Avant Bise oral care lines. Rohto's international presence also makes it a relevant comparable for Wakamoto's geographic expansion strategy.
• Kobayashi Pharmaceutical: Kobayashi Pharmaceutical is a Japanese household-name OTC and self-medication company with overlapping categories in digestive remedies, oral care, and lifestyle supplements. It is the closest public-comparable peer to Wakamoto in scale, product breadth, and consumer-brand-led distribution through drugstores in Japan.
• Kowa Company: Kowa operates a consumer healthcare business in Japan encompassing OTC pharmaceuticals, supplements, and traditional remedies. Comparable mid-size Japan pharma profile with a similar mix of legacy digestive/internal medicine products and newer lifestyle supplement extensions.
• Sato Pharmaceutical: Sato Pharmaceutical is a mid-sized Japanese OTC and self-medication company with products spanning gastrointestinal remedies, topical pain relief, and oral care. Comparable in scale (small-mid Japan pharma) and distribution model (pharmacy/drugstore-led), making Sato a clean small-cap peer.
• Lion Corporation: Lion Corporation is a Japanese household products company with a substantial OTC pharmaceutical and oral care business (Lion Dental, healthcare products). It directly overlaps Wakamoto's oral care category (Avant Bise) and shares the consumer-drugstore distribution channel playbook in Japan.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/avan_wkmt
• YouTubeyoutube.com/@wakamoto_official
• Facebookfacebook.com/wakamoto.fanpage
• Instagraminstagram.com/wakamoto_gwt
• LinkedInlinkedin.com/company/wakamoto-pharmaceutical-co-ltd

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wakamoto Pharmaceutical